Clinical trials: Tuberculous Meningitis, active
Tuberculous Meningitis
Intensified Short Course Regimen for TBM in Adults
Tuberculous meningitis (TBM) is the most lethal form of extra pulmonary tuberculosis. This devastating disease kills almost a third of its sufferers and disables a significant proportion of the survivors.
- Trial name
- INSHORT (NCT05917340)
- Testing
- High dose rifampicin (25mg/kg), Moxifloxacin 400mg, Aspirin 150 mg
- Where
- India
- Volunteers
- 372 people
- Sponsor
- Indian Council of Medical Research
Tuberculosis, Meningitis
Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis
Contezolid is a novel oxazolidinone antibiotic developed by Shanghai Mengke Pharmaceutical Co., Ltd., which successfully went public in 2021.
- Trial name
- NCT06811025
- Testing
- Contezolid, Linezolid (LZD)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Beijing Chest Hospital
Tuberculous Meningitis
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
The purpose of this study is to compare a 6-month regimen of high-dose rifampicin (RIF), high-dose isoniazid (INH), linezolid (LZD), and pyrazinamide (PZA) versus the World Health Organization (WHO) standard of care (SOC)…
- Trial name
- NCT05383742
- Testing
- Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD)
- Where
- 18 sites in Brazil, India and 10 more
- Volunteers
- 330 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculous Meningitis
Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis
INTENSE-TBM is randomized controlled, phase III, multicenter, 2 x 2 factorial plan superiority trial assessing the efficacity of two interventions to reduce mortality from tuberculous meningitis (TBM) in adolescents and adults…
- Trial name
- INTENSE-TBM (NCT04145258)
- Testing
- Aspirin, WHO TBM treatment, Intensified TBM treatment
- Where
- 13 sites in Côte d’Ivoire, Madagascar and 2 more
- Volunteers
- 768 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Tuberculous Meningitis, HIV
BPaLMZ for TB Meningitis
This two-stage study will compare consented research participants with tuberculous meningitis receiving experimental Bedaquiline (B), Pretomanid (Pa), Linezolid (L); Moxifloxacin (M), Pyrazinamide (Z) known as (BPaLMZ) to…
- Conditions
- Tuberculous Meningitis, HIV, Meningitis, TB - Tuberculosis
- Trial name
- BPaLMZ (NCT07227779)
- Testing
- BPaLMZ Regimen
- Where
- 2 sites in Uganda
- Volunteers
- 312 people
- Sponsor
- David Boulware
Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology)
Adjunctive Doxycycline for Central Nervous System Tuberculosis
Although tuberculosis is now considered a treatable disease, central nervous system tuberculosis (CNS-TB) when managed with the current standard-of-care (SOC), still has mortality rates ranging from 30-50% even in tertiary…
- Conditions
- Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology), Tuberculosis, Central Nervous System, Tuberculosis; Meningoencephalitis (Etiology)
- Trial name
- DIRECT (NCT06446245)
- Testing
- Doxycycline, Anti Tuberculosis Drug, Adjunctive corticosteroid
- Where
- 6 sites in Indonesia, Malaysia and 1 more
- Volunteers
- 200 people
- Sponsor
- National University Hospital, Singapore
Tuberculous Meningitis, HIV I Infection
Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis
Randomized phase II clinical trial which aims to assess the impact on 3-month mortality and safety of adding adalimumab to standard treatment (anti-tuberculosis drugs and corticosteroids) in HIV patients with tuberculosis…
- Trial name
- TIMPANI (NCT05590455)
- Testing
- Adalimumab Injection
- Where
- 3 sites in Brazil, Mozambique and 1 more
- Volunteers
- 130 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Tuberculosis Meningitis
Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis
AlpE is a novel drug combination under development for the treatment of TB, with several positive attributes for TBM, including rapid bactericidal activity.
- Trial name
- NCT07350174
- Testing
- HRZE, HRZE plus Alpe375, HRZE plus AlpE500
- Volunteers
- 64 people
- Sponsor
- BioVersys AG